Home/Filings/4/0000313143-13-000170
4//SEC Filing

HAEMONETICS CORP 4

Accession 0000313143-13-000170

$HAECIK 0000313143operating

Filed

Oct 24, 8:00 PM ET

Accepted

Oct 25, 7:24 PM ET

Size

15.7 KB

Accession

0000313143-13-000170

Insider Transaction Report

Form 4
Period: 2013-10-23
ALLEN PETER M
Chief Marketing Officer
Transactions
  • Award

    Common Stock

    2013-10-23+3,24030,037 total
Holdings
  • Non-Qualified Stock Option (right to buy)

    Exercise: $13.05From: 2005-05-05Exp: 2014-05-05Common Stock (30,000 underlying)
    30,000
  • Non-Qualified Stock Option (right to buy)

    Exercise: $27.27From: 2009-10-22Exp: 2015-10-22Common Stock (30,494 underlying)
    30,494
  • Non-Qualified Stock Option (right to buy)

    Exercise: $25.54From: 2008-10-24Exp: 2014-10-24Common Stock (36,426 underlying)
    36,426
  • Non-Qualified Stock Option (right to buy)

    Exercise: $27.50From: 2011-10-27Exp: 2017-10-27Common Stock (30,776 underlying)
    30,776
  • Non-Qualified Stock Option (right to buy)

    Exercise: $26.47From: 2010-10-27Exp: 2016-10-27Common Stock (31,340 underlying)
    31,340
  • Non-Qualified Stock Option (right to buy)

    Exercise: $39.05From: 2013-10-24Exp: 2019-10-24Common Stock (32,192 underlying)
    32,192
  • Non-Qualified Stock Option (right to buy)

    Exercise: $30.67From: 2012-10-25Exp: 2018-10-25Common Stock (30,740 underlying)
    30,740
  • Performance Shares

    Exercise: $0.00From: 2017-03-31Exp: 2017-12-31Common Stock (25,000 underlying)
    25,000
Footnotes (3)
  • [F1]Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
  • [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
  • [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

Issuer

HAEMONETICS CORP

CIK 0000313143

Entity typeoperating
IncorporatedMA

Related Parties

1
  • filerCIK 0000313143

Filing Metadata

Form type
4
Filed
Oct 24, 8:00 PM ET
Accepted
Oct 25, 7:24 PM ET
Size
15.7 KB